MONTREAL, QUEBEC -- (MARKET WIRE) -- September 29, 2006 -- MethylGene Inc. (TSX: MYG) reported in vitro preclinical results further supporting the antifungal potential of MG3290 in human fungal infections. The poster presentations were held at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA and at the 3rd Annual North American Genetic ABC Workshop in Frederick, MD.
